Spero Therapeutics, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for SPRO, updated each market day.
SPRO AI Sentiment
AI predicts Spero Therapeutics, Inc. Common Stock stock is likely to decrease over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Spero Therapeutics, Inc. Common Stock
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Sector
Exchange
Market Cap
$160,938,350
Cap Tier
Employees
25
Headquarters
CAMBRIDGE, MA
Listed Since
Nov. 2, 2017
SPRO Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
SPRO Volatility
Spero Therapeutics, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
